Dr. Carl Awh presents the first report of an implant that may transform the treatment of wet macular degeneration.
Dr. Awh presented the results of the Phase 2 LADDER clinical trial at the 36th Annual Meeting of the American Society of Retina Specialists in Vancouver, BC, Canada on July 25, 2018. Tennessee Retina was a clinical trial site in LADDER, which evaluated a small implant that releases ranibizumab (Lucentis®) into the eye over many months, potentially eliminating the need for monthly eye injections. Click the weblink below for more information about this exciting new treatment. Tennessee Retina has been selected as a site for the final, Phase 3 clinical trial, which will begin later this year.
Posted on 08/06/2018 10:43 AM by Tennessee Retina